Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 1,201–1,300 of 4,628
Torrisi, S. E., Kahn, N. C., Wälscher, J., Sarmand, N., Polke, M., Kehler, L., Eichinger, M., Heußel, C. P., Palmucci, S., Sambataro, F. M., et al. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0937-0 · Cited by 38
Chen, L., Hou, J., Fu, X., Chen, X., Wu, J., & Han, X. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1669997 · Cited by 33
“Although the FDA has approved two new drugs Pirfenidone and Nidanib in 2014, these two drugs can only slowdown the pulmonary dysfunction but neither of them can be a cure for IPF [6].”
BackgroundAn Open-label Study With Pirfenidone on Chronic Hypersensitivity Pneumonitis
Mateos‐Toledo, H., Mejía, M. E., Rodríguez-Barreto, Ó., Mejía-Hurtado, J. G., Rojas‐Serrano, J., Estrada, A., Castillo-Pedroza, J., Castillo-Castillo, K., Gaxiola, M., Buendía-Roldán, I., et al. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2019.08.019 · Cited by 33
Self-citationOncostatin M in the Regulation of Connective Tissue Cells and Macrophages in Pulmonary Disease
Richards, C. D., & Botelho, F. M. (2019) · Biomedicines · doi:10.3390/biomedicines7040095 · Cited by 37
“In clinical trials targeting tyrosine kinase signaling of TGF-β, the drug Nintedanib showed slowing but not a stoppage of progression, and may generate severe side effects [26,27].”
BackgroundNADPH Oxidase Inhibition in Fibrotic Pathologies
Bernard, K. F., & Thannickal, V. J. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8032 · Cited by 34
Effects of Nintedanib in an Animal Model of Liver Fibrosis
Wollin, L., Togbe, D., & Ryffel, B. (2020) · BioMed Research International · doi:10.1155/2020/3867198 · Cited by 37
“The INPULSIS [7] and TOMORROW [8] trials demonstrated the beneficial effects of nintedanib in patients with IPF.”
BackgroundMethodFibrotic Hypersensitivity Pneumonitis: Diagnosis and Management
Varone, F., Iovene, B., Sgalla, G., et al. (2020) · Lung · doi:10.1007/s00408-020-00360-3 · Cited by 33
Self-citationMoor, C. C., Mostard, R. L. M., Grutters, J. C., Bresser, P., Aerts, J. G. J. V., Dirksen, C. D., Kimman, M., & Wijsenbeek, M. S. (2020) · Respiratory Research · doi:10.1186/s12931-020-01458-1 · Cited by 33
“Furthermore, no significant differences in all-cause mortality and frequency of side-effects were found between the two drugs [2, 3, 5, 21].”
BackgroundNathan, S. D., Wanger, J. S., Zibrak, J. D., Wencel, M. L., Burg, C., & Stauffer, J. L. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1816831 · Cited by 38
Tzilas, V., Τzouvelekis, Α., Bouros, E., Karampitsakos, Τ., Ntassiou, M., Avdoula, E., Trachalaki, A., Antoniou, K. M., Raghu, G., & Bouros, D. E. (2020) · ERJ Open Research · doi:10.1183/23120541.00152-2020 · Cited by 36
Self-citationEfficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Sugino, K., Ono, H., Watanabe, N., Shimizu, S., Ando, M., Tsuboi, E., Homma, S. A., & Kishi, K. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01595-3 · Cited by 35
Hino, T., Lee, K. S., Han, J., Hata, A., Ishigami, K., & Hatabu, H. (2021) · Korean Journal of Radiology · doi:10.3348/kjr.2020.1132 · Cited by 34
Kreus, M., Lehtonen, S. T., Skarp, S., & Kaarteenaho, R. L. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250109 · Cited by 36
“Furthermore, a tyrosine kinase inhibitor, namely nintedanib is used in the treatment of both IPF and lung cancer [7, 8] and moreover, myofibroblasts, are believed to act as principal pathogenetic cell types both in IPF and lung cancer [9, 10].”
BackgroundRomano, E., Rosa, I., Fioretto, B. S., Matucci‐Cerinic, M., & Manetti, M. (2021) · Life · doi:10.3390/life11070610 · Cited by 40
The Role of miRNAs in Extracellular Matrix Repair and Chronic Fibrotic Lung Diseases
Usman, K., Hsieh, A., & Hackett, T. (2021) · Cells · doi:10.3390/cells10071706 · Cited by 38
Beghé, B., Cerri, S., Fabbri, L. M., & Marchioni, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179292 · Cited by 35
Cough in Idiopathic Pulmonary Fibrosis
Mann, J., Goh, N. S. L., Holland, A. E., & Khor, Y. H. (2021) · Frontiers in Rehabilitation Sciences · doi:10.3389/fresc.2021.751798 · Cited by 40
Guler, S. A., Sarbu, A.-C., Stalder, O., Allanore, Y., Bernardino, V., Distler, J. H. W., Gabrielli, A., Hoffmann‐Vold, A., Matucci‐Cerinic, M., Müller‐Ladner, U., et al. (2023) · Thorax · doi:10.1136/thorax-2023-220541 · Cited by 39
Jaguin, M., Fardel, O., & Lecureur, V. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.04.007 · Cited by 35
Fletcher, S., Jones, M. G., Renzoni, E. A., Parfrey, H., Hoyles, R. K., Spinks, K., Kokosi, M. A., Kwok, A., Warburton, C. J., Titmuss, V., et al. (2018) · ERJ Open Research · doi:10.1183/23120541.00049-2018 · Cited by 33
Self-citationNicotine Modulates Growth Factors and MicroRNA to Promote Inflammatory and Fibrotic Processes
Ebrahimpour, A., Shrestha, S., Bonnen, M., Eissa, N. T., Raghu, G., & Ghebre, Y. T. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.252650 · Cited by 36
“However, these drugs only slow the disease progression in patients with mild-to-moderate disease (Raghu and Thickett, 2013; Richeldi et al., 2014).”
BackgroundSelf-citationCleemput, J. V., Sonaglioni, A., Wuyts, W. A., Bengus, M., Stauffer, J. L., & Harari, S. A. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0857-z · Cited by 34
Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis
Rimner, A., Moore, Z., Lobaugh, S. M., Geyer, A. I., Gelblum, D. Y., Abdulnour, R.-E. E., Shepherd, A. F., Shaverdian, N., Wu, A. J.-C., Cuaron, J. J., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.02.030 · Cited by 39
Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis
Maher, T. M., Stowasser, S., Voß, F., Bendstrup, E. M., Kreuter, M., Martínez, F. J., Sime, P. J., & Stock, C. (2023) · Respirology · doi:10.1111/resp.14579 · Cited by 37
Self-citationMechanisms of Bleomycin-induced Lung Fibrosis: A Review of Therapeutic Targets and Approaches
Mohammed, S. M., Al-Saedi, H. F. S., Mohammed, A. Q., Amir, A. A., Radi, U. K., Sattar, R., Ahmad, I., Ramadan, M. F., Alshahrani, M. Y., Balasim, H. M., et al. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01384-9 · Cited by 46
Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences
Harari, S. A., & Caminati, A. (2015) · European Respiratory Review · doi:10.1183/16000617.0042-2015 · Cited by 36
Acute exacerbations complicating interstitial lung disease
Ryerson, C. J., & Collard, H. R. (2014) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000073 · Cited by 32
Self-citationRiches, D. W. H., Backos, D. S., & Redente, E. F. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.01.005 · Cited by 32
Gruden, J. F., Panse, P. M., Gotway, M. B., Jensen, E. A., Wellnitz, C. V., & Wesselius, L. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.15.14525 · Cited by 34
Martin, M. D., Chung, J. H., & Kanne, J. P. (2016) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000204 · Cited by 38
Nonalcoholic fatty liver disease is associated with decreased lung function
Lee, C., Choi, S. H., Chung, G. E., Park, B., & Kwak, M. (2018) · Liver International · doi:10.1111/liv.13860 · Cited by 37
Kim, H.-Y., Kim, M., Kim, S., Joen, D., & Lee, K. (2018) · Molecules · doi:10.3390/molecules23081974 · Cited by 37
“The clinical trials of NDN showed a significant reduction of forced vital capacity (FVC) in IPF patients, demonstrating that NDN should become the standard treatment for IPF patients [14,25].”
BackgroundResultZou, R. H., Nouraie, M. S., Chen, X., Saul, M. I., Kaminski, N., Gibson, K. F., Kass, D. J., & Lindell, K. O. (2019) · Journal of Palliative Medicine · doi:10.1089/jpm.2018.0400 · Cited by 33
Fukuizumi, A., Minegishi, Y., Omori, M., Atsumi, K., Takano, N., Hisakane, K., Takahashi, S., KOBAYASHI, K. P., Sugano, T., Takeuchi, S., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01516-9 · Cited by 32
Self-citationIdiopathic Pulmonary Fibrosis and Lung Transplantation: When it is Feasible
Balestro, E., Cocconcelli, E., Tinè, M., Biondini, D., Faccioli, E., Saetta, M. P., & Rea, F. (2019) · Medicina · doi:10.3390/medicina55100702 · Cited by 38
“Despite the availability of effective pharmacologic treatments for IPF [15,16], LTx is so far the only treatment with proven benefit on survival for carefully selected patients with advanced disease and respiratory failure.”
BackgroundClinical course and management of idiopathic pulmonary fibrosis
Quinn, C., Wisse, A., & Manns, S. T. (2019) · Multidisciplinary Respiratory Medicine · doi:10.1186/s40248-019-0197-0 · Cited by 46
Shiratori, T., Tanaka, H., Tabe, C., Tsuchiya, J., Ishioka, Y., Itoga, M., Taima, K., Takanashi, S., & Tasaka, S. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13437 · Cited by 32
Minegishi, Y., Gemma, A., Homma, S. A., Kishi, K., Azuma, A., Ogura, T., Hamada, N., Taniguchi, H., Hattori, N., Nishioka, Y., et al. (2020) · ERJ Open Research · doi:10.1183/23120541.00184-2019 · Cited by 31
Self-citationHe, N., Wang, Y., Huang, Y. L., Wang, X., Chen, L., & Lv, C. (2020) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2020.128565 · Cited by 32
Li, X., Liu, X., Deng, R., Gao, S., Jiang, Q., Liu, R., Li, H., Yang, M., Zhai, Y., Zhang, S., et al. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153428 · Cited by 36
Johannson, K. A., Lethebe, B. C., Assayag, D., Fisher, J. H., Kolb, M. R. J., Morisset, J., Shapera, S., Gershon, A. S., Hambly, N., Khalil, N., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202102-216oc · Cited by 40
Self-citationClusters of comorbidities in idiopathic pulmonary fibrosis
Prior, T. S., Hoyer, N., Hilberg, O., Shaker, S. B., Davidsen, J. R., Rasmussen, F., & Bendstrup, E. M. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106490 · Cited by 38
Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases
Tomassetti, S., Ravaglia, C., Puglisi, S., Ryu, J. H., Colby, T. V., Cavazza, A., Wells, A. U., Pavone, M., Vancheri, C., Lavorini, F., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202104-466oc · Cited by 35
Lasky, J. A., Case, A., Unterman, A., Kreuter, M., Scholand, M. B., Chaudhary, S., Lofaro, L. R., Johnson, M., Huang, J., Bhorade, S. M., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202107-897oc · Cited by 34
Antifibrotic Drug Nintedanib Inhibits CSF1R to Promote IL-4–associated Tissue Repair Macrophages
Watson, C. K., Schloesser, D., Fundel‐Clemens, K., Lerner, C., Gabler, S., Baskaran, P., Wohnhaas, C. T., Dichtl, S., Huber, H. J., Ask, K., et al. (2023) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0021oc · Cited by 38
The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?
Jiang, A., Liu, N., Wang, J., Zheng, X., Ren, M., Zhang, W., & Yao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1022228 · Cited by 34
Fala, L. (2015) · PubMed · Cited by 33
Virakul, S., Heutz, J. W., Dalm, V. A. S. H., Peeters, R. P., Paridaens, D. A., van den Bosch, W. A., Hirankarn, N., van Hagen, P. M., & Dik, W. A. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.05.023 · Cited by 32
Podolanczuk, A. J., & Cottin, V. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02454-9 · Cited by 45
Self-citationHSP47: A Therapeutic Target in Pulmonary Fibrosis
Sakamoto, N., Okuno, D., Tokito, T., Yura, H., Kido, T., Ishimoto, H., Tanaka, Y., & Mukae, H. (2023) · Biomedicines · doi:10.3390/biomedicines11092387 · Cited by 37
“Criteria for PF-ILD and PPF include worsening respiratory symptoms, physiological evidence of disease progression, and radiological evidence of disease progression.”
BackgroundInfluentialCirculating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
Summer, R. S., Todd, J. L., Neely, M. L., Lobo, L. J., Namen, A. M., Newby, L. K., Shafazand, S., Suliman, S. A., Heßlinger, C., Keller, S., et al. (2024) · Respiratory Research · doi:10.1186/s12931-023-02644-7 · Cited by 35
Leavy, O. C., Kawano-Dourado, L. B., Stewart, I. D., Quint, J. K., Solomon, J. J., Borie, R., Crestani, B., Wain, L. V., Jenkins, G. R., Dieudé, P., et al. (2024) · Thorax · doi:10.1136/thorax-2023-220856 · Cited by 36
Pharmacological treatment of idiopathic pulmonary fibrosis: an update
Spagnolo, P., Wells, A. U., & Collard, H. R. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.01.001 · Cited by 33
Self-citationSwigris, J. J., Olson, A. L., & Brown, K. K. (2016) · Patient Related Outcome Measures · doi:10.2147/prom.s74857 · Cited by 37
Self-citationKim, M., Lee, S. M., Song, J., Do, K., Lee, H. J., Lim, S., Choe, J., Park, K. J., Park, H. J., Kim, H. J., et al. (2017) · European Journal of Radiology · doi:10.1016/j.ejrad.2017.03.018 · Cited by 33
Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis
Moor, C. C., Heukels, P., Kool, M., & Wijsenbeek, M. S. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00226 · Cited by 34
Chambers, D. M., Moretti, L., Zhang, J. J., Cooper, S. W., Chambers, D. M., Santangelo, P. J., & Barker, T. H. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003658 · Cited by 36
“The medical management of fibrotic diseases, such as pulmonary fibrosis, has enjoyed recent success with the approval of pirfenidone, an “anti-fibrotic agent,” and nintedanib, an inhibitor of multiple tyrosine kinase receptors, after years of failed clinical trials with a variety of other agents, including anti-inflam…”
BackgroundLiang, J., Liu, N., Liu, X., Mena, J. M., Xie, T., Geng, Y., Huan, C., Zhang, Y., Taghavifar, F., Huang, G., et al. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0033oc · Cited by 33
Self-citationDuan, F., Barrón, G. M., Meliton, A. Y., Mutlu, G. M., Dulin, N. O., & Schuger, L. A. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0028oc · Cited by 38
Mackintosh, J. A., Munsif, M., Ranzenbacher, L., Thomson, C., Musk, M., Snell, G. I., Glanville, A. R., Chambers, D. C., & Hopkins, P. M.-A. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.02.005 · Cited by 35
Kasam, R. K., Reddy, G. B., Jegga, A. G., & Madala, S. K. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00532 · Cited by 30
Novel idiopathic pulmonary fibrosis susceptibility variants revealed by deep sequencing
Lorenzo-Salazar, J. M., Ma, S., Jou, J., Hou, P., Guillén‐Guío, B., Allen, R. J., Jenkins, G. R., Wain, L. V., Oldham, J. M., Noth, I., et al. (2019) · ERJ Open Research · doi:10.1183/23120541.00071-2019 · Cited by 34
Update in Interstitial Lung Disease 2019
Montesi, S. B., Fisher, J. H., Martínez, F. J., Selman, M., Pardo, A., & Johannson, K. A. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202002-0360up · Cited by 37
Self-citationType I Collagen Signaling Regulates Opposing Fibrotic Pathways through α2β1 Integrin
Agarwal, M., Goheen, M., Jia, S., Ling, S., White, E. S., & Kim, K. K. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0150oc · Cited by 34
Dhooria, S., Agarwal, R., Sehgal, I. S., Prasad, K. T., Muth, V., Garg, M. K., Bal, A., Aggarwal, A. N., & Behera, D. (2020) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v37i2.8718 · Cited by 40
Fibroblasts and their responses to chronic injury in pulmonary fibrosis
Wu, B., Tang, L. F., & Kapoor, M. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.12.003 · Cited by 37
Wong, A. M., Lu, J., Dorfman, A., McInnis, P., Famouri, M., Manary, D., Lee, J. R. H., & Lynch, M. (2021) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2021.764047 · Cited by 34
“A very critical step in the treatment and management of pulmonary fibrosis is the assessment of lung function decline, as this guides clinicians to determining the best course of treatment and management ranging from oxygen therapy and pulmonary rehabilitation to pharmacological agents (pirfenidone [1] and nintedanib…”
BackgroundThe kidney matrisome in health, aging, and disease
Lausecker, F., Lennon, R., & Randles, M. J. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.029 · Cited by 30
Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis
Thong, L., McElduff, E. J., & Henry, M. T. (2023) · Life · doi:10.3390/life13020486 · Cited by 37
“Nintedanib Ofev® (Tyrosine Kinase Inhibitor) INPULSIS-1 & -2 [54] 2014 52-week, multicenter randomized, double blind, and placebo controlled Nintedanib reduced the decline in FVC.”
BackgroundFibro-Stenosing Crohn’s Disease: What Is New and What Is Next?
Solitano, V., Buono, A. D., Gabbiadini, R., Wozny, M., Repici, A., Spinelli, A., Vetrano, S., & Armuzzi, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093052 · Cited by 37
“The former inhibits TGF-β and TNFα, whereas the latter is thought to inhibit PDGF, fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF) receptor signaling [98,99].”
BackgroundIdiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Strykowski, R. K., & Adegunsoye, A. (2023) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2023.01.010 · Cited by 36
Pulmonary Sequelae of COVID-19: Focus on Interstitial Lung Disease
Johnston, J., Dorrian, D., Linden, D. A., Stanel, S. C., Rivera‐Ortega, P., & Chaudhuri, N. (2023) · Cells · doi:10.3390/cells12182238 · Cited by 31
“The current standard of care treatment includes antifibrotic medication to slow down progression medication (Pirfenidone and Nintedanib) [13,14], symptom management, and lung transplant in selected cases.”
BackgroundInfluentialZheng, B., Marinescu, D.-C., Hague, C. J., Müller, N. L., Murphy, D. T., Churg, A., Wright, J. L., Al-Arnawoot, A., Bilawich, A.-M., Bourgouin, P., et al. (2024) · Rheumatology · doi:10.1093/rheumatology/keae076 · Cited by 39
Self-citationIdiopathic pulmonary fibrosis mortality: update on trends in the modern treatment era
Podolanczuk, A. J., & Raghu, G. (2024) · European Respiratory Journal · doi:10.1183/13993003.01305-2024 · Cited by 31
Self-citationPI3K/Akt in IPF: untangling fibrosis and charting therapies
Bhatt, J., Ghigo, A., & Hirsch, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1549277 · Cited by 41
Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies
Chen, X., Zhang, J., Guo, L., Wu, C., Zhou, J., Xu, M., Mo, L., Li, Y., & He, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02532-0 · Cited by 59
Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway
Abdalla, M., Thompson, L., Gurley, E., Burke, S. M., Ujjin, J., Newsome, R., & Somanath, P. R. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.11.008 · Cited by 36
Treatment of rapidly progressive systemic sclerosis: current and futures perspectives
Mendoza, F. A., Mansoor, M., & Jiménez, S. A. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1114454 · Cited by 33
Nikolaou, A. I., Ninou, I., Kokotou, M. G., Kaffe, E., Afantitis, A., Aidinis, V., & Kokotos, G. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00232 · Cited by 32
SIS3, a specific inhibitor of smad3, attenuates bleomycin-induced pulmonary fibrosis in mice
Shou, J., Cao, J., Zhang, S., Sun, R., Zhao, M., Chen, K., Su, S. B., Yang, J., & Yang, T. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.06.072 · Cited by 31
Holtze, C. H., Flaherty, K. R., Kreuter, M., Luppi, F., Moua, T., Vancheri, C., & Scholand, M. B. (2018) · European Respiratory Review · doi:10.1183/16000617.0078-2018 · Cited by 33
Self-citationTRAIL signals through the ubiquitin ligase MID1 to promote pulmonary fibrosis
Collison, A., Li, J., de Siqueira, A. P., Lv, X., Toop, H. D., Morris, J. C., Starkey, M. R., Hansbro, P. M., Zhang, J., & Mattes, J. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0786-x · Cited by 33
Hirahara, K., Aoki, A., Morimoto, Y., Kiuchi, M., Okano, M., & Nakayama, T. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00735-6 · Cited by 30
Ikeda, S., Sekine, A., Baba, T., Katano, T., Tabata, E., Shintani, R., Sadoyama, S., Yamakawa, H., Oda, T., Okuda, R., et al. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0841-7 · Cited by 30
Quintela-Fandiño, M., Apala, J. V., Malón, D., Mouron, S. A., Hornedo, J., González‐Cortijo, L., Colomer, R., & Guerra, J. A. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1152-x · Cited by 30
Tyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices
Rieg, A. D., Bünting, N. A., Cranen, C., Suleiman, S., Spillner, J. W., Schnöring, H., Schröder, T., von Stillfried, S. F., Braunschweig, T. A., Manley, P. W., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1074-2 · Cited by 32
Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
Valenzuela, C., Torrisi, S. E., Kahn, N. C., Quaresma, M., Stowasser, S., & Kreuter, M. (2020) · Respiratory Research · doi:10.1186/s12931-019-1269-6 · Cited by 32
Self-citationNathan, S. D., Yang, M., Morgenthien, E. A., & Stauffer, J. L. (2020) · European Respiratory Journal · doi:10.1183/13993003.02151-2019 · Cited by 35
Southern, B. D. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.ccc026 · Cited by 31
Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib
Makino, S. (2020) · Modern Rheumatology · doi:10.1080/14397595.2020.1826665 · Cited by 35
New Perspectives on the Aberrant Alveolar Repair of Idiopathic Pulmonary Fibrosis
Wang, Z. N., & Tang, X. X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.580026 · Cited by 35
“Both of them show an effect on improving lung function (Noble et al., 2011; King et al., 2014; Richeldi et al., 2014), but fail to reverse lung fibrosis or bring further survival benefit.”
BackgroundKato, M., Sasaki, S., Tateyama, M., Arai, Y., Motomura, H., Sumiyoshi, I., Ochi, Y., Watanabe, J. A., Ihara, H., Togo, S., et al. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s284819 · Cited by 36
Long non‐coding RNAs: Promising new targets in pulmonary fibrosis
Zhang, S., Chen, H., Yue, D., Blackwell, T. S., Lv, C., & Song, X. (2021) · The Journal of Gene Medicine · doi:10.1002/jgm.3318 · Cited by 31
Caminati, A., Madotto, F., Conti, S., Cesana, G., Mantovani, L. G., & Harari, S. A. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02651-w · Cited by 33
Hariri, L. P., Roden, A. C., Chung, J. H., Danoff, S. K., Manjarres, D. C. G., Hartwig, M. G., Kheir, F. M., King, C. S., Kreider, M. E., Lynch, D. A., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202009-1179fr · Cited by 35
Post-COVID-19 pulmonary fibrosis: A case series and review of literature
Rai, D. K., Kumar, S., & Sahay, N. (2021) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2126_20 · Cited by 31
Tyrosine kinases regulate chondrocyte hypertrophy: promising drug targets for Osteoarthritis
Blanco, M. N. F., Garcia, H. D., Legeai‐Mallet, L., & van Osch, G. J. V. M. (2021) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2021.07.003 · Cited by 34
Khan, F., Howard, L., Hearson, G., Edwards, C., Barber, C., Jones, S., Wilson, A. M., Maher, T. M., Saini, G., Stewart, I., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202105-612rl · Cited by 31
Althobiani, M. A., Alqahtani, J. S., Hurst, J. R., Russell, A., & Porter, J. C. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001088 · Cited by 38
Jegal, Y., Park, J. S., Kim, S. Y., Yoo, H., Jeong, S. H., Song, J. W., Lee, J. H., Lee, H. L., Choi, S. M., Kim, Y. W., et al. (2021) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2021.0123 · Cited by 38
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.